ABSTRACT
INTRODUCTION Chronological age (CA) is a predictor of adverse COVID-19 outcomes; however, CA alone has not shown to be the better predictor of adverse outcomes in COVID-19 as it does not capture individual responses to SARS-CoV-2 infection. Here, we evaluated the influence of aging metrics PhenoAge and PhenoAccelAge on the adaptive responses to SARS-CoV-2 infection in hospitalized patients.
METHODS We assessed cases admitted to a COVID-19 reference center in Mexico City. PhenoAge and PhenoAccelAge were estimated using laboratory values at admission. Cox proportional hazards models were fitted to estimate risk for COVID-19 lethality and adverse outcomes (ICU admission, intubation, or death), and k-means clustering was performed to explore reproducible patterns of adaptive response to SARS-CoV-2 infection using PhenoAge components.
RESULTS We included 1069 subjects of whom 401 presented critical illness and 204 died. PhenoAge was a better predictor of adverse outcomes and lethality compared to CA and SpO2 and its predictive capacity was sustained for all age groups. Patients with responses associated PhenoAccelAge >0 had higher risk of death and critical illness compared to those who had values according to CA (log-rank p<0.001). Using unsupervised clustering we identified four adaptive responses to SARS-CoV-2 infection: 1) Inflammaging associated with CA, 2) adaptive metabolic dysfunction associated with cardio-metabolic comorbidities, 3) adaptive unfavorable hematological response, and 4) response associated with favorable outcomes.
CONCLUSIONS Adaptive responses related to accelerated aging metrics are linked to adverse COVID-19 outcomes and have unique and distinguishable features. PhenoAge is a better predictor of adverse outcomes compared to CA.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All proceedings were approved by the INCMNSZ Research and Ethics Committee, written informed consent was waived due to the observational nature of the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available from the Institutional Data Access Ethics Committee (contact via the corresponding author) for researchers who meet the criteria for access to confidential data. Code for all statistical analyses is available at http://github.com/oyaxbell/covid_phenoage.
